Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409694 | 1.00 | HSD17B1 (0.33) | HSD17B1HSD17B2FYNADORA3EGLN1 | |
| SCHEMBL2417948 | 0.87 | GRM5 (0.36) | ADORA3DHODH | |
| SCHEMBL2412695 | 0.87 | PRMT5 (0.40) | HSD17B1HSD17B2FYNADORA3EGLN1 | |
| SCHEMBL2417950 | 0.87 | GRM5 (0.36) | ADORA3DHODH | |
| SCHEMBL2412704 | 0.87 | PRMT5 (0.40) | HSD17B1HSD17B2FYNADORA3EGLN1 | |
| SCHEMBL2413305 | 0.87 | NPC1 (0.38) | ADORA3NAAA | |
| SCHEMBL2413310 | 0.87 | NPC1 (0.38) | ADORA3NAAA | |
| SCHEMBL2411109 | 0.85 | HSD17B1 (0.49) | HSD17B1HSD17B2FYNADORA3 | |
| SCHEMBL2411104 | 0.85 | HSD17B1 (0.49) | HSD17B1HSD17B2FYNADORA3 | |
| SCHEMBL2414591 | 0.84 | MKNK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | HSD17B1 1048/4885HSD17B2 1172/4885FYN 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.